Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

89 results about "Clostridium difficile" patented technology

Aptamers against clostridium difficile

Compositions comprising aptamers capable of specifically binding to a surface protein of Clostridium difficile spore are provided. A method for detecting, enriching, separating, and / or isolating Clostridium difficile spores is provided.
Owner:LIV PROCESS INC

Clostridiodes difficile growth inhibitor

Provided is a growth inhibitor for Clostridioides difficile. A growth inhibitor for Clostridioides difficile, comprising killed Enterococcus faecalis. Also provided are a parenteral pharmaceutical preparation, a bactericide, a disinfectant, an antibacterial agent, a sanitizer or a detergent for inhibiting the growth of Clostridioides difficile.
Owner:NUTRI CO LTD

Clostridium difficile multi-locus genotyping detection kit and application thereof

The present application belongs to the technical field of bacterial detection, and particularly relates to a Clostridium difficile multi-locus genotyping detection kit and application thereof. The present application aims to provide a new method to directly type a main Clostridium difficile strain sequence type (ST). The technical scheme of the present application is a multiplex fluorescence PCR primer set and probe for Clostridium difficile multi-locus genotyping detection, wherein the primer and probe are shown in Seq ID No. 1-18. The present application discloses a multiplex fluorescence PCR reagent for 7 main ST types of Clostridium difficile based on a fluorescence PCR-dissolution curve method. The reagent can simultaneously detect 7 main ST types of Clostridium difficile in the same PCR reaction system.
Owner:YUNNAN PROVINCIAL CENT FOR DISEASE CONTROL & PREVENTION

Pathogenic bacteria

ActiveUS12171734B2Organic active ingredientsAntibacterial agentsClostridium difficile (bacteria)Antibiotic drug
The present invention relates to pathogenic bacteria, and is particularly concerned with treating, preventing or ameliorating bacterial infections using novel antibiotic compositions. The invention is especially useful for treating infections of Bacillus and Clostridia species, such as Clostridium difficile, Staphylococcus aureus and Mycobacterium spp. The invention extends to pharmaceutical compositions comprising such formulations. The invention also extends to methods for identifying aerobic Bacillus spp., which exhibit antibacterial activity against other bacteria, such as C. difficile, and to methods for isolating active antibacterial compositions from these aerobic Bacillus spp.
Owner:SPOREGEN

Antibodies against Clostridium difficile-specific proteins, magnetic bead-antibody conjugates and their applications

The present invention discloses an antibody against Clostridium difficile specific protein, a magnetic bead-antibody conjugate and its application. The monoclonal antibody is any one of monoclonal antibody CD1, monoclonal antibody CD2, monoclonal antibody CD3 and monoclonal antibody CD4. The magnetic bead-antibody conjugate is formed by conjugating a monoclonal antibody with activated carboxyl magnetic beads to obtain the magnetic bead-antibody conjugate. Based on the magnetic bead-antibody conjugate sorting method, antibody magnetic beads that couple and recognize the Clostridium difficile secreted proteins TcdA, TcdB, the highly expressed GDH on the surface of Clostridium difficile, and the LPxTG of Clostridium difficile are used to capture Clostridium difficile, achieving the purpose of rapidly isolating Clostridium difficile from fecal samples. The present invention is based on the immunomagnetic bead separation technology of antigen-antibody reaction for separation, with the characteristics of being rapid, simple, having high enrichment efficiency and strong specificity. The present invention can be used to isolate and remove Clostridium difficile in fecal microbiota transplantation, and can also be used for strain identification and sequencing.
Owner:MEI YI TIAN BIOLOGICAL MEDICINE WUHAN CO LTD

Primer and probe combination, kit and method for detecting gastrointestinal pathogenic bacteria

The invention relates to a primer and probe combination, a kit and a method for detecting gastrointestinal tract pathogenic bacteria. The gastrointestinal pathogenic bacteria comprise vibrio cholerae, vibrio parahaemolyticus, salmonella, shigella, diarrheagenic escherichia coli, campylobacter, yersinia enterocolons, clostridium difficile, cronobacter sakazakii, aeromonas hydrophila, plesiomonas shigelloides and vibrio fluvialis. The primer and the probe group can be independently used for PCR amplification detection and can be combined in the same reaction system and reaction procedure for multiple PCR amplification detection, and the primers and the probes aiming at different pathogenic bacteria cannot interfere with each other during multiple PCR amplification detection. The primer and probe combination covers various types of gastrointestinal pathogenic bacteria, and is high in sensitivity, low in detection limit, good in specificity and wide in application prospect.
Owner:GUANGZHOU WONDFO BIOTECH

A protein inhibitor for Clostridium difficile exotoxin B, a composition containing the same and its application

The present invention provides a protein inhibitor against Clostridium difficile exotoxin B, a composition comprising the same and its application. The protein inhibitor 43829 (SEQ ID No.: 1) or H3 (SEQ ID No.: 2) of the present invention can broadly bind to the TcdB RBI-1 site; 5N2 (SEQ ID No.: 3) can broadly bind to the TcdB RBI-2 site. The present invention also provides an Fc homodimer and an Fc heterodimer fused to the protein inhibitor of the present application. The protein inhibitor of the present application and its composition successfully neutralize the main subtypes of TcdB in vitro and in vivo, providing an important basis for the development of new strategies for treating difficult infectious diseases such as CDI by de novo design.
Owner:WESTLAKE LAB OF LIFE SCI & BIOMEDICINE

Monoclonal antibody-containing composition for suppressing clostridium difficile bacteria

The present invention relates to a composition comprising a monoclonal antibody binding to Clostridium difficile (C. difficile) for inhibiting a growth of Clostridium difficile (C. difficile), and a use thereof. In addition, the present invention discloses the composition for treating an inflammatory bowel disease, and a use thereof.
Owner:THE UNIV OF TOKYO

A monoclonal antibody against Clostridium difficile toxin B and its preparation method and application

The present invention relates to the field of medical biological antibodies, specifically a monoclonal antibody against Clostridium difficile toxin B, the amino acid sequences of its heavy chain CDR1, CDR2, and CDR3 are shown in SEQ ID NO:1-3, respectively, and the amino acid sequences of its light chain CDR1, CDR2, and CDR3 are shown in SEQ ID NO:4-6, respectively. The present invention also provides a preparation method and application of the monoclonal antibody. The mouse-derived neutralizing antibody screened by the present invention has good antibody activity and has the potential to be developed into a marketed product.
Owner:LANZHOU INST OF BIOLOGICAL PROD

Primer group for simultaneously detecting four types of horse digestive tract bacteria and application of primer group

The invention discloses a primer group for simultaneously detecting four equine digestive tract bacteria and application thereof, the primer group comprises primer sequences as shown in SEQ ID NO: 1-8, and the four equine digestive tract bacteria are salmonella enteritidis, salmonella typhimurium, clostridium difficile and lawsonia intracellular. Extracting total DNA (deoxyribonucleic acid) of a sample to be detected by using the excrement sample nucleic acid extraction kit; the total DNA is used as a template, and the primer group is used for multiple PCR reaction to obtain an amplification curve. According to the invention, a primer sequence with high sensitivity and specificity is adopted, so that the quality of a detection result is ensured; the detection method is simple to operate, time-saving and labor-saving; the detection flux is high, and the reagent consumable cost is low.
Owner:NANJING ZHUOYI BIOTECHNOLOGY CO LTD

Agents for the treatment of non-replicating bacteria

PCT designated stage expiredWO2025049804A3Peptide/protein ingredientsPeptidesDiseaseBacillus cereus
In one aspect, the invention relates to compounds useful as hybrid antibiotics, acting as both activators of the ClpP protease and inhibitors of RNA polymerase activity. Also disclosed are methods of using the disclosed compounds in the treatment of infectious diseases such as, for example, biofilm-mediated diseases and infectious diseases due to prosthetic joint infections, intracellular bacteria, and Gram-positive bacteria (e.g., Gram-positive bacteria selected from Bacillus anthracis, Bacillus cereus, Bacillus subtilis, Clostridium difficile, Clostridium tetani, Clostridium botulinum, Clostridium perfringens, Corynebacterium diphtheria, Enterococcus faecalis, Enterococcus faecium, Listeria monocytogenes, Listeria ivanovii, Micrococcus luteus, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus hyicus, Staphylococcus intermedius, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Owner:ST JUDE CHILDRENS RES HOSPITAL INC +1

Stable vaccine against Clostridium difficile

The present invention relates to a synthetic saccharide of general formulate (I) that is related to Clostridium difficile PS-II cell-surface polysaccharide and conjugate thereof. Said synthetic saccharide, said conjugate and pharmaceutical composition containing said synthetic saccharide or said conjugate are useful for prevention and / or treatment of diseases associated with Clostridium difficile. Furthermore, the synthetic saccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies against Clostridium difficile bacteria.
Owner:IDORSIA PHARMACEUTICALS LTD

Antimicrobial composition and method of using the same

To provide: an antimicrobial composition containing hydrogen peroxide that has increased efficacy against microorganisms and has no unpleasant odor; a wiping product; a method for disinfecting a hard surface; and an antimicrobial composition precursor.SOLUTION: An antimicrobial composition comprises: a hydrogen peroxide source; and a peroxide adjuvant, the peroxide adjuvant comprising an organic acid and / or salt thereof having a pKa from about 1 to about 6, the antimicrobial composition being free of acetic acid. The peroxide adjuvant is present in the composition in an amount sufficient for the composition to achieve at least 3 log10 reduction after a three minute contact time when tested against Clostridium difficile according to ASTM Test Methods E2197-11 and E2839-11.SELECTED DRAWING: Figure 1
Owner:ARXADA LLC

Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof

This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and / or toxin B.
Owner:VALNEVA AUSTRIA GMBH +1

Clostridium difficile binary toxin neutralizing antibodies

The present invention provides isolated Clostridium difficile binary toxin antibodies that are capable of neutralizing binary toxin with high potency, polypeptides and nucleic acids encoding the same, and methods of use thereof.
Owner:UNIV OF MARYLAND

Antimicrobial Compositions and Uses for Treatment of Clostridioides difficile, Mycobacterium tuberculosis, and Enterococcus faecalis Infection

Provided herein are compositions to treat Clostridioides difficile (C. difficile), Mycobacterium tuberculosis (M. tuberculosis) and Enterococcus faecalis (E. faecalis). These compositions are related to the known compounds (+)-Puupehenone and (+)-ent-Chromazonarol, which are both naturally occurring products. The new compositions were shown to potently inhibit both growth and toxin production of C. difficile as well as inhibit the growth and survival of both replicating and dormant M. tuberculosis. In the United States the C. difficile burden is approximately 453,000 hospital cases and 29,000 deaths annually. Globally, about 10 million people fall ill from tuberculosis and 1.4 million died from the disease. In addition, the known compound (+)-ent-Chromazonarol (10) was found for the first time to strongly inhibit the growth of E. faecalis. E. faecalis has grown drug resistant to vancomycin. In 2017, Vancomycin-Resistant Enterococci (VRE) caused an estimated 54,500 infections among hospitalized patients and 5,400 estimated deaths in the United States.
Owner:UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION INC +1

Aptamers Against Clostridium Difficile

PendingUS20260185105A1AptamerSporeling
Compositions comprising aptamers capable of specifically binding to a surface protein of Clostridium difficile spore are provided. A method for detecting, enriching, separating, and / or isolating Clostridium difficile spores is provided.
Owner:LIV PROCESS INC

Protease preparation for the treatment of toxins

PendingJP2025521857AAntibacterial agentsPowder deliveryProtease preparationInfectious Colitis
A method for the treatment of one or more toxins in a subject is provided, the method comprising administering to the subject a therapeutically effective amount of a serine protease that enzymatically cleaves a specific toxin. Also provided is a method for preventing the progression of disease in a subject infected with Clostridioides difficile (CD), diarrhea, or infectious colitis, the method comprising administering to the subject a therapeutically effective amount of the protease. The protease retains its activity up to 65°C. Treatment with the protease in mice infected with CD provided a 10-fold survival benefit compared to CD-infected untreated mice. TIFF2025521857000010.tif62147
Owner:QUEENS UNIV +1

Intestinal flora marker related to children inflammatory bowel disease, product and application of intestinal flora marker

The invention discloses an intestinal flora marker related to a children inflammatory bowel disease, a product and application of the intestinal flora marker. The intestinal flora marker disclosed by the invention is one or more of streptococcus salivarius, bacteroides ovatus, bacteroides vulgaris, clostridium altaicum, actinomycetes decayed tooth and clostridium difficile, and can be applied to prediction and diagnosis of patients with the inflammatory bowel disease in children, the diagnosis process is completely noninvasive, and the accuracy is high.
Owner:TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH

Yeast-based immunotherapy against Clostridium difficile infection

ActiveUS12384833B2Antibacterial agentsFungiDiseaseCamelid
Antibody-based binding agents derived from human and camelid immunoglobulins are described, as well as strains of yeast engineered to secrete the binding agents, and methods of treating and preventing Clostridium difficile infections using the engineered strains of yeast. These binding agents recognize and bind with specificity to Clostridium difficile toxin A and / or toxin B and in some cases exhibit toxin neutralizing activity. The binding agents include camelid VHH peptide monomers, linked groups of VHH peptide monomers, VHH peptide monomers joined to antibody Fc domains, and VHH peptide monomers joined to IgG antibodies.
Owner:UNIV OF MARYLAND

Non-protein metabolite of Thailand enterococcus d5B, application of non-protein metabolite and anti-clostridium difficile antibacterial composition

The invention provides a non-protein metabolite of Thailand enterococcus d5B and application of the non-protein metabolite. The non-protein metabolite of the Thailand enterococcus d5B is a product obtained after enzymolysis of cell-free supernate of the Thailand enterococcus d5B by protease; the collection number of Thailand enterococcus d5B is CCTCC (China Center for Type Culture Collection) NO: M 20232279, and the Thailand enterococcus d5B is collected in the China Center for Type Culture Collection on November 20, 2023. The inventor discovers that the non-protein metabolite of the Thailand enterococcus d5B can play a role in killing clostridium difficile in a concentration-dependent manner, a good antibacterial effect can be achieved when the concentration of CFS containing the non-protein metabolite is 1 mu g / mu L or above, and the CFS containing the non-protein metabolite is an effective clostridium difficile bacteriostatic active component; the non-protein metabolite of the Thailand enterococcus has the antibacterial effect on the clostridium difficile for the first time at home and abroad, and has extremely high application value in the aspect of clinical treatment.
Owner:SHANGHAI JIAOTONG UNIV SCHOOL OF MEDICINE

Clostridium difficile phage recombinant lysin Lys51, its preparation method and application

PendingCN122326634AEscherichia coliLysin
This invention discloses the Clostridium difficile phage recombinant lyase Lys51, its preparation method, and its application, relating to the field of genetic engineering technology. The invention involves introducing the recombinant plasmid pET-28a-SUMO-Lys51 into Escherichia coli BL21(DE3) competent cells via heat shock transformation; screening to obtain the recombinant engineered bacterium BL21(DE3)-pET-28a-SUMO-Lys51; constructing the recombinant plasmid pET-28a-SUMO-Lys51 and the recombinant engineered bacterium BL21(DE3)-pET-28a-SUMO-Lys51, further inducing the expression of Clostridium difficile phage recombinant lyase Lys51 in the recombinant engineered bacterium BL21(DE3)-pET-28a-SUMO-Lys51, and then purifying it to achieve the complete process for preparing Clostridium difficile phage recombinant lyase Lys51.
Owner:JILIN UNIVERSITY

Camel source single-domain antibody CB3 for recognizing clostridium difficile methylase CamA and application of camel source single-domain antibody CB3

The invention discloses a camel source single-domain antibody CB3 for recognizing linear B cell epitope in clostridium difficile methylase CamA and application of the camel source single-domain antibody CB3. The nucleotide sequence of the camel source single-domain antibody CB3 is as shown in SEQ ID NO: 1, and the amino acid sequence of the camel source single-domain antibody CB3 is as shown in SEQ ID NO: 2. The camel source single-domain antibody CB3 disclosed by the invention has the advantages of strong specificity, high sensitivity, good accuracy and the like, and it is proved that the camel source single-domain antibody CB3 can be used for detecting recombinant expressed CD-CamA and endogenous CD-CamA by methods such as enzyme-linked immunosorbent assay (ELISA) and western blot hybridization (WB).
Owner:ZHEJIANG MEDICAL COLLEGE

Agents for the treatment of non-replicating bacteria

PCT designated stage expiredWO2025049804A2PeptidesCyclic peptide ingredientsDiseaseBacillus cereus
In one aspect, the invention relates to compounds useful as hybrid antibiotics, acting as both activators of the ClpP protease and inhibitors of RNA polymerase activity. Also disclosed are methods of using the disclosed compounds in the treatment of infectious diseases such as, for example, biofilm-mediated diseases and infectious diseases due to prosthetic joint infections, intracellular bacteria, and Gram-positive bacteria (e.g., Gram-positive bacteria selected from Bacillus anthracis, Bacillus cereus, Bacillus subtilis, Clostridium difficile, Clostridium tetani, Clostridium botulinum, Clostridium perfringens, Corynebacterium diphtheria, Enterococcus faecalis, Enterococcus faecium, Listeria monocytogenes, Listeria ivanovii, Micrococcus luteus, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus hyicus, Staphylococcus intermedius, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Owner:ST JUDE CHILDRENS RES HOSPITAL INC +1

Compositions and methods of reducing or preventing clostridioides difficile colonization

Embodiments of the present disclosure relate to a method of preventing and / or reducing C. difficile colonization of a surface. In certain embodiments, the aptamer can be used to kill and / or deactivate a C. difficile spore. In certain embodiments, the aptamer can be used to increase the sporicidal activity of a sporicidal agent. Embodiments of the present disclosure relate to the use of aptamers which specifically bind to C. difficile surface proteins, for example proteins located on the surface of a C. difficile spore.
Owner:LIV PROCESS INC

A trace element composition for improving the fermentation efficiency of Clostridium difficile producing ethanol under conditions containing CO2 and H2 syngas and its application.

PendingCN122326507ABiotechnologyTrace element composition
This invention discloses a trace element composition and its application for improving the fermentation efficiency of *Clostridium autoethanogenum* under conditions containing CO2 and H2 syngas, belonging to the field of microbial fermentation technology. The trace element composition comprises the following components: 1.5% nitroglycerin, 3% magnesium sulfate, 0.5% manganese sulfate, 0.1% ferrous sulfate, 0.18% cobalt sulfate, 0.1% calcium chloride, 0.18% zinc sulfate, 0.01% copper sulfate, 0.02% potassium aluminum sulfate, 0.01% boric acid, 0.01% sodium molybdate, 0.03% nickel chloride, and 0.004% sodium tungstate. Using the trace element composition of this invention, after 4 days of fermentation under conditions containing CO2 and H2 syngas (CO2:H2=1:2, CO-free), the cell concentration is nearly twice that of the control group without the composition, and the syngas utilization rate is significantly improved. This invention provides an effective technical solution to the problem of low fermentation efficiency of self-producing ethanol Clostridium in a pure CO2 and H2 system, and has good prospects for industrial application.
Owner:TIANJIN UNIV OF SCI & TECH +1